Market Overview:
The global melphalan injection market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for better treatment options, and growing awareness about available treatments. The global melphalan injection market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into 50mg/vial and 10mg/vial. On the basis of application, the market is segmented into hospital, clinics, and recovery center. The hospital segment dominates this market owing to increased use for chemotherapy in hospitals. Geographically, this market is divided into North America (U.S., Canada), Latin America (Mexico), Europe (Germany France Italy Spain U.K.), Asia Pacific (China Japan India South Korea Australia New Zealand), Middle East & Africa (GCC Countries Turkey Iran South Africa).
Product Definition:
A chemotherapy drug used to treat various types of cancer, including ovarian, breast, and multiple myeloma. It is a type of alkylating agent that works by damaging the DNA of cancer cells.
50mg/vial:
50mg/vial is used for the treatment of cancer. It's a form of cytotoxic chemical (cancer-killing) medication that interferes with cell reproduction. The drug was developed by Parke-Doxie Laboratories in the early 1960s and patented in 1970.
10mg/vial:
10mg/vial is the most common concentration of Melphalan used for chemotherapy. It is a form of L-asparaginase, an enzyme that helps in the destruction of cancer cells by breaking their cell walls. Chemotherapy with this drug has shown to shrink tumors in animals and people with various types of cancers when it is given intravenously or orally. However, there are no drugs approved by the U.
Application Insights:
The hospital application segment dominated the global melphalan injection market in 2017, accounting for over 60% of the total revenue. The segment is expected to witness significant growth during the forecast period owing to increasing cancer cases and awareness regarding early treatment. In addition, a rising number of hospitals coupled with improved healthcare infrastructure in developing countries such as India and China will boost industry growth over the forecast period.
The clinics application segment accounted for around 19% of total revenue share in 2017 due to growing awareness about early diagnosis and treatment among general practitioners (GPs). Furthermore, increasing availability of low cost generic drugs will also fuel industry expansion during this study period. However, recovery centers are anticipated to be fastest growing sub-segment due largely on factors such as high cost associated with them which may limit its overall penetration rate over the next few years.
Regional Analysis:
North America dominated the global melphalan injection market in 2017. The presence of a large number of manufacturers coupled with high healthcare expenditure and favorable reimbursement policies are some factors contributing to its largest share. In addition, increasing R&D activities by various companies is also expected to contribute towards the growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising patient awareness levels regarding oncological diseases, improving healthcare infrastructure and growing disposable income especially in developing countries such as China & India which are major consumers of this drug.
Growth Factors:
- Increasing incidence of blood cancer: The increasing incidence of blood cancer is one of the major growth drivers for the Melphalan Injection market. Blood cancers are caused by the abnormal growth and multiplication of cells in the blood and bone marrow, which hampers their ability to fight infection and results in excessive bleeding. According to a study by American Cancer Society, it is estimated that around 171,000 new cases of leukemia will be diagnosed in 2018 in United States alone. This high incidence rate is expected to drive demand for Melphalan Injection products over the forecast period.
- Rising awareness about early diagnosis and treatment: The rising awareness about early diagnosis and treatment options for blood cancers is another key factor driving demand for Melphalan Injection products globally. Blood cancers can often be cured if they are detected at an early stage; however, most patients are not aware of these symptoms until it is too late. This has led to increased focus on raising awareness about these diseases among healthcare professionals as well as general population worldwide, which is expected to boost demand for Melphalan Injection products over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Melphalan Injection Market Research Report
By Type
50mg/vial, 10mg/vial
By Application
Hospital, Clinics, Recovery Center
By Companies
Fresenius Kabi, Dr. Reddy's, Athenex, Meitheal Pharmaceutical, GSK, Mylan, Sagent, Spectrum Pharmaceuticals, Par Pharmaceuticals, Mediclone Biotech
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
224
Number of Tables & Figures
157
Customization Available
Yes, the report can be customized as per your need.
Global Melphalan Injection Market Report Segments:
The global Melphalan Injection market is segmented on the basis of:
Types
50mg/vial, 10mg/vial
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinics, Recovery Center
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Fresenius Kabi
- Dr. Reddy's
- Athenex
- Meitheal Pharmaceutical
- GSK
- Mylan
- Sagent
- Spectrum Pharmaceuticals
- Par Pharmaceuticals
- Mediclone Biotech
Highlights of The Melphalan Injection Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 50mg/vial
- 10mg/vial
- By Application:
- Hospital
- Clinics
- Recovery Center
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Melphalan Injection Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Melphalan injection is a chemotherapy medication used to treat cancer. It works by killing cancer cells.
Some of the major players in the melphalan injection market are Fresenius Kabi, Dr. Reddy's, Athenex, Meitheal Pharmaceutical, GSK, Mylan, Sagent, Spectrum Pharmaceuticals, Par Pharmaceuticals, Mediclone Biotech.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Melphalan Injection Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Melphalan Injection Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Melphalan Injection Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Melphalan Injection Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Melphalan Injection Market Size & Forecast, 2020-2028
4.5.1 Melphalan Injection Market Size and Y-o-Y Growth
4.5.2 Melphalan Injection Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 50mg/vial
5.2.2 10mg/vial
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinics
6.2.3 Recovery Center
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Melphalan Injection Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Melphalan Injection Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 50mg/vial
9.6.2 10mg/vial
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinics
9.10.3 Recovery Center
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 50mg/vial
10.6.2 10mg/vial
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinics
10.10.3 Recovery Center
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 50mg/vial
11.6.2 10mg/vial
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinics
11.10.3 Recovery Center
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 50mg/vial
12.6.2 10mg/vial
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinics
12.10.3 Recovery Center
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 50mg/vial
13.6.2 10mg/vial
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinics
13.10.3 Recovery Center
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Melphalan Injection Market: Competitive Dashboard
14.2 Global Melphalan Injection Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Fresenius Kabi
14.3.2 Dr. Reddy's
14.3.3 Athenex
14.3.4 Meitheal Pharmaceutical
14.3.5 GSK
14.3.6 Mylan
14.3.7 Sagent
14.3.8 Spectrum Pharmaceuticals
14.3.9 Par Pharmaceuticals
14.3.10 Mediclone Biotech
